Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.83 |
| ▸ | ERBB2 | P04626 | 10/20 | 0.83 |
| ▸ | STK3 | Q13188 | 6/20 | 0.83 |
| ▸ | STK4 | Q13043 | 5/20 | 0.83 |
| ▸ | SRC | P12931 | 2/20 | 0.83 |
| ▸ | KDR | P35968 | 2/20 | 0.83 |
| ▸ | BTK | Q06187 | 2/20 | 0.83 |
| ▸ | STK25 | O00506 | 1/20 | 0.83 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.83 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.83 |
| ▸ | GAK | O14976 | 1/20 | 0.83 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.83 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.83 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.83 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.83 |
| ▸ | STK17B | O94768 | 1/20 | 0.83 |
| ▸ | STK10 | O94804 | 1/20 | 0.83 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.83 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.83 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29801718 | 1.00 | EGFR (0.83) | EGFRERBB2STK3STK4SRC | |
| SCHEMBL2386963 | 1.00 | EGFR (0.83) | EGFRERBB2STK3STK4SRC | |
| SCHEMBL5020000 | 0.95 | EGFR (0.83) | EGFRERBB2STK3STK4SRC | |
| SCHEMBL4540604 | 0.95 | EGFR (0.82) | EGFRERBB2STK3STK4SRC | |
| SCHEMBL4540611 | 0.95 | EGFR (0.82) | EGFRERBB2STK3STK4SRC | |
| SCHEMBL17570820 | 0.94 | EGFR (0.88) | EGFRERBB2STK3STK4SRC | |
| SCHEMBL18780473 | 0.93 | EGFR (0.87) | EGFRERBB2STK3STK4SRC | |
| SCHEMBL31661612 | 0.93 | EGFR (0.87) | EGFRERBB2STK3STK4SRC | |
| SCHEMBL30185817 | 0.92 | EGFR (0.85) | EGFRERBB2STK3STK4SRC | |
| SCHEMBL28970453 | 0.92 | EGFR (0.85) | EGFRERBB2STK3STK4SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092046-A1 | MALEATE SALTS OF (E)-N-{4-[3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO]-3-CYANO-7-ETHOXY-6-QUINOLINYL}-4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF | WYETH LLC (US) | 2026-04-02 | — | — | US | disclosed |
| US-10035788-B2 | Maleate salts of (E)-N-{4[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof | WYETH LLC (US) | 2018-07-31 | — | — | US | disclosed |
| US-10035788-B2 | Maleate salts of (E)-N-{4[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof | WYETH LLC (US) | 2018-07-31 | — | — | US | disclosed |
| US-20170320852-A1 | MALEATE SALTS OF (E)-N--4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF | WYETH LLC | 2017-11-09 | — | — | US | disclosed |
| US-20170320852-A1 | MALEATE SALTS OF (E)-N--4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF | WYETH LLC | 2017-11-09 | — | — | US | disclosed |
| US-9630946-B2 | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof | WYETH LLC (US) | 2017-04-25 | — | — | US | disclosed |
| US-9630946-B2 | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof | WYETH LLC (US) | 2017-04-25 | — | — | US | disclosed |
| EP-2626353-B1 | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof | WYETH LLC (US) | 2016-11-23 | — | — | EP | disclosed |
| EP-2626353-B1 | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof | WYETH LLC (US) | 2016-11-23 | — | — | EP | disclosed |
| EP-3088398-A1 | MALEATE SALTS OF (E)-N-{4-[3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO]-3-CYANO-7-ETHOXY-6-QUINOLINYL}-4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF | Wyeth LLC (US) | 2016-11-02 | — | — | EP | disclosed |
| US-8173814-B2 | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof | WYETH LLC (US) | 2012-05-08 | — | — | US | disclosed |
| US-8022216-B2 | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof | WYETH LLC (US) | 2011-09-20 | — | — | US | disclosed |
| US-8022216-B2 | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof | WYETH LLC (US) | 2011-09-20 | — | — | US | disclosed |
| EP-2258698-A2 | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof | Wyeth LLC (US) | 2010-12-08 | — | — | EP | disclosed |
| EP-2258698-A2 | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof | Wyeth LLC (US) | 2010-12-08 | — | — | EP | disclosed |
| EP-2212311-A2 | MALEATE SALTS OF (E)-N-{4-Ý3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO¨-3-CYANO-7-ETHOXY-6-QUINOLINYL}-4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF | Wyeth LLC (US) | 2010-08-04 | — | — | EP | disclosed |
| US-20090176827-A1 | MALEATE SALTS OF (E)-N--4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF | WYETH (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176827-A1 | MALEATE SALTS OF (E)-N--4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF | WYETH (US) | 2009-07-09 | — | — | US | disclosed |
| WO-2009052264-A2 | MALEATE SALTS OF (E)-N-{4-[3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO]-3-CYANO-7-ETHOXY-6-QUINOLINYL}-4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF | WYETH (US) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009052264-A2 | MALEATE SALTS OF (E)-N-{4-[3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO]-3-CYANO-7-ETHOXY-6-QUINOLINYL}-4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF | WYETH (US) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320852-A1 | MALEATE SALTS OF (E)-N--4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF | EGFR, ERBB4, ALK | EGFR 1/4885ERBB2 7/4885STK3 392/4885 |
| US-10035788-B2 | Maleate salts of (E)-N-{4[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof | EGFR, ERBB4, ERBB3 | EGFR 1/4885ERBB2 4/4885STK3 436/4885 |
| US-20260092046-A1 | MALEATE SALTS OF (E)-N-{4-[3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO]-3-CYANO-7-ETHOXY-6-QUINOLINYL}-4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF | EGFR, MET, ERBB2 | EGFR 1/4885ERBB2 3/4885STK3 570/4885 |
| US-20090176827-A1 | MALEATE SALTS OF (E)-N--4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF | EGFR, ERBB4, ALK | EGFR 1/4885ERBB2 4/4885STK3 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.